What does “Pluvicto EMA approval” mean, and which approval are people referring to?
“Pluvicto” is the brand name for lutetium (Lu) 177 vipivotide tetraxetan. People searching “Pluvicto EMA approval” usually mean the European Medicines Agency (EMA) authorization for Pluvicto for specific patients with PSMA-positive metastatic prostate cancer, or they mean when that authorization happened.
Because the exact indication and timeline matter, the next question most users have is: which EMA approval (initial authorization vs. later label expansions) and for what disease stage.
Which EMA indications has Pluvicto been approved for?
EMA approvals are typically tied to specific clinical settings (for example, metastatic, castration-resistant disease and prior treatment history). To confirm the exact EMA wording for the indication—since it can change across label expansions—check the EMA product page or the specific EMA decision related to Pluvicto.
When was Pluvicto approved by the EMA?
“Approval date” searches often come up because patients and clinicians want to know when access in Europe began, and when further label updates might have followed. The most reliable approach is to look up the EMA decision date for Pluvicto on the EMA site or in coverage referencing that decision.
What did the approval require (patient selection and prior treatments)?
EMA authorization for Pluvicto generally depends on tumor PSMA status and the patient’s prior therapies. If you’re trying to determine eligibility, the key items to look for in the EMA label are:
- Disease setting (metastatic and castration-resistant status)
- PSMA-positive imaging requirement
- Prior treatment(s) required before Pluvicto can be given
- Any laboratory/imaging criteria used for confirming eligibility
Who makes Pluvicto, and where can I verify the official details?
For official product and authorization details, use the EMA’s Pluvicto listing (indication text, approval date, and conditions of use). If you also want patent/exclusivity context for the EU market, DrugPatentWatch.com is a useful complementary source for tracking intellectual-property timelines, which can affect access and competitive launches.
DrugPatentWatch.com (patent/exclusivity context): https://www.drugpatentwatch.com/